E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared on LinkedIn:
“In the latest installment of my Blood Cancer United Behind the Breakthroughs blog series, I’m excited to share highlights from my recent conversation with two remarkable voices representing the impact of precision medicine: Dr. Brian Druker, who transformed cancer treatment by developing the first precision medicine to target cancer cells while sparing healthy ones; and Mel Mann, a chronic myeloid leukemia (CML) survivor who gained more than 30 years of life, thanks to that discovery.
Their story is a powerful example of what’s possible when science, persistence, and purpose come together to give patients more time…more treasured moments with family and friends.
Other articles about Blood Cancer on OncoDaily.